Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle Sells 12,210 Shares

Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Exelixis Price Performance

EXEL opened at $35.07 on Thursday. The firm has a market capitalization of $9.82 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. The business’s 50-day moving average is $34.16 and its two-hundred day moving average is $31.11. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $37.59.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on EXEL. Brookline Capital Management began coverage on Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. Stephens reiterated an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Morgan Stanley raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. Stifel Nicolaus boosted their price objective on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday, February 12th. Finally, UBS Group boosted their price target on Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.24.

Hedge Funds Weigh In On Exelixis

Several institutional investors and hedge funds have recently bought and sold shares of the company. Seizert Capital Partners LLC boosted its position in shares of Exelixis by 8.0% in the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock worth $12,195,000 after purchasing an additional 34,875 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in Exelixis by 124.0% in the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares during the last quarter. Tri Ri Asset Management Corp acquired a new stake in Exelixis in the third quarter worth about $4,396,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after acquiring an additional 20,641 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in shares of Exelixis during the third quarter valued at about $577,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.